var data={"title":"Apraclonidine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Apraclonidine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5660?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=apraclonidine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Apraclonidine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136267\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Iopidine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136268\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Iopidine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136303\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Alpha<sub>2</sub> Agonist, Ophthalmic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136270\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intraocular pressure reduction: </b>Ophthalmic:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.5%: Instill 1 to 2 drops in the affected eye(s) 3 times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1%: Instill 1 drop in operative eye 1 hour prior to anterior segment laser surgery, second drop in same eye immediately upon completion of procedure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136271\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136272\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; monitor cardiovascular parameters closely. Use with caution in patients with chronic renal failure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136273\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; monitor cardiovascular parameters closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136253\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Ophthalmic: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Iopidine: 0.5% (5 mL, 10 mL); 1% (1 ea) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5% (5 mL, 10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136238\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136255\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Ophthalmic: For topical ophthalmic use only; not for injection or oral administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">0.5% solution: Wait 5 minutes between instillation of other ophthalmic agents to avoid washout of previous dose. After topical instillation, finger pressure should be applied to lacrimal sac to decrease drainage into the nose and throat and minimize possible systemic absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% solution: Use a separate container for each single drop dose; discard container after each use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136254\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intraocular pressure reduction:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>0.5% solution:</b> Short-term, adjunctive therapy in patients who require additional reduction of IOP</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>1% solution:</b> Prevention and treatment of postsurgical intraocular pressure (IOP) elevation following argon laser trabeculoplasty, argon laser iridotomy or Nd:YAG posterior capsulotomy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136309\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Iopidine may be confused with indapamide, iodine, Lodine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136245\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">5% to 15%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Xerostomia (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eye discomfort, eye pruritus, ocular hyperemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 5%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac arrhythmia (&lt;3%), chest pain (&lt;3%), facial edema (&lt;3%), peripheral edema (&lt;3%), localized blanching</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Altered sense of smell (&lt;3%), ataxia (&lt;3%), depression (&lt;3%), dizziness (&lt;3%), drowsiness (&lt;3%), headache (&lt;3%), insomnia (&lt;3%), malaise (&lt;3%), nervousness (&lt;3%), paresthesia (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Contact dermatitis (&lt;3%), dermatitis (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (&lt;3%), dysgeusia (&lt;3%), nausea (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (&lt;3%), weakness (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision, conjunctivitis, dry eye syndrome, eyelid edema, eye discharge, foreign body sensation of eye, lacrimation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Asthma (&lt;3%), dry nose (&lt;3%), dyspnea (&lt;3%), pharyngitis (&lt;3%), rhinitis (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Blepharitis, blepharoconjunctivitis, bradycardia, conjunctival edema, corneal erosion, corneal infiltrates, corneal staining, crusting of eyelid, epithelial keratopathy, erythema of eyelid, eyelid disease, eyelid retraction, eye irritation, eye pain, follicular conjunctivitis, hypersensitivity reaction, keratitis, ocular edema, photophobia, scaling of eyelid, visual disturbance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136258\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to apraclonidine, clonidine, or any component of the formulation; concomitant use with MAO inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Children and adolescents &lt;18 years old.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136242\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause dizziness and somnolence, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Use may lead to allergic-like reactions, including hyperemia, pruritus, discomfort, tearing, foreign body sensation, and edema of the lid and conjunctiva; if these symptoms occur, discontinue use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe uncontrolled cardiovascular disease (eg, hypertension), coronary insufficiency, recent myocardial infarction, cerebrovascular disease, Raynaud disease, and thromboangiitis obliterans.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Use with caution in depressed patients and monitor signs/symptoms of depression; therapy is associated infrequently with depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Close monitoring of cardiovascular parameters is recommended in patients with hepatic impairment; clonidine (structurally related to apraclonidine) administered systemically undergoes partial hepatic metabolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Close monitoring of cardiovascular parameters is recommended in patients with renal impairment; use with caution in patients with chronic renal failure. Topical apraclonidine has not been studied in patients with renal impairment; however, the half-life of clonidine (structurally related to apraclonidine) administered systemically is increased significantly in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasovagal reactions: Potential for a vasovagal attack to occur; use with caution in patients with history of vasovagal reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact lens wearers: Some products contain benzalkonium chloride which may be absorbed by soft contact lenses; contact lenses should be removed during instillation; may be reinserted 15 minutes after instillation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For topical ophthalmic use only; not for injection or oral administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tachyphylaxis: The IOP-lowering efficacy may decrease over time in some patients; most patients experience a benefit for less than one month; routinely monitor IOP.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298767\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136247\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8863&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May diminish the therapeutic effect of Alpha2-Agonists (Ophthalmic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If the combination cannot be avoided, monitor for decreased effects of alpha2-agonists if mirtazapine is initiated/dose increased, or increased effects if mirtazapine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Apraclonidine. Monoamine Oxidase Inhibitors may increase the serum concentration of Apraclonidine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May diminish the therapeutic effect of Alpha2-Agonists (Ophthalmic).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136260\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease potential exposure to the fetus (Samples 1988).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20547462\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if apraclonidine is present in breast milk. The manufacturer recommends that caution be exercised when administering apraclonidine 0.5% to breastfeeding women and that breastfeeding be discontinued on the day apraclonidine 1% is administered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136251\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Closely monitor patients who develop exaggerated reductions in intraocular pressure; visual fields (periodically for glaucoma patients on maximally tolerated medical therapy using 0.5% solution to delay surgery); tachyphylaxis; cardiovascular parameters in patients with renal and/or hepatic impairment; depression in depressed patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136241\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Apraclonidine is a potent alpha-adrenergic agent similar to clonidine; relatively selective for alpha<sub>2</sub>-receptors but does retain some binding to alpha<sub>1</sub>-receptors; appears to result in reduction of aqueous humor formation; its penetration through the blood-brain barrier is more polar than clonidine which reduces its penetration through the blood-brain barrier and suggests that its pharmacological profile is characterized by peripheral rather than central effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136257\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Decreased intraocular pressure: 3 to 5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination, systemic: 0.5% solution: 8 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136259\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Apraclonidine HCl Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (5 mL): $86.77</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Iopidine Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5% (5 mL): $200.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (1): $33.27</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136261\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alfadrops (IN);</li>\n      <li>Chen Ze (CN);</li>\n      <li>Iopidine (AR, AT, AU, BB, BE, BF, BG, BJ, BR, CH, DE, DK, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, IE, IL, IT, KE, KR, LR, LU, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, NZ, PE, PL, PT, PY, QA, SA, SC, SD, SE, SG, SL, SN, TH, TN, TR, TZ, UG, VE, ZA, ZM, ZW);</li>\n      <li>Iopimax (ES)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Iopidine 0.5% (apraclonidine ophthalmic solution) [prescribing information]. Fort Worth, TX: Alcon; March 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iopidine 1% (apraclonidine ophthalmic solution) [prescribing information]. Fort Worth, TX: Alcon; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iopidine 0.5% and 1% (apraclonidine ophthalmic solution) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. <i>Am J Ophthalmol</i>. 1988;106(5):616-623.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/apraclonidine-drug-information/abstract-text/2903673/pubmed\" target=\"_blank\" id=\"2903673\">2903673</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8863 Version 110.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F136267\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F136268\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F136303\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F136270\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F136271\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F136272\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F136273\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F136253\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F136238\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F136255\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F136254\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F136309\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F136245\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F136258\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F136242\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298767\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F136247\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F136260\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20547462\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F136251\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F136241\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F136257\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F136259\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F136261\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8863|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=apraclonidine-patient-drug-information\" class=\"drug drug_patient\">Apraclonidine: Patient drug information</a></li></ul></div></div>","javascript":null}